```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05  CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14  2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14  2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14  CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21  IPC search and display fields enhanced in CA/CAplus with the
                  IPC reform
 NEWS  8  DEC 23  New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                  USPAT2
 NEWS  9  JAN 13  IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13  New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                  INPADOC
 NEWS 11  JAN 17  Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17  IPC 8 in the WPI family of databases including WPIFV
 NEWS 13  JAN 30  Saved answer limit increased
 NEWS 14  JAN 31  Monthly current-awareness alert (SDI) frequency
                  added to TULSA

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:29:02 ON 02 FEB 2006

=> "solid phase"
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> file caplus biosis
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

```
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      2.52       2.52

FILE 'CAPLUS' ENTERED AT 14:35:58 ON 02 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:35:58 ON 02 FEB 2006
Copyright (c) 2006 The Thomson Corporation

=> solid (s) phase
L1      215795 SOLID (S) PHASE

=> "polystyrene latx particle"
L2           0 "POLYSTYRENE LATX PARTICLE"

=> polystyrene
L3      149966 POLYSTYRENE

=> latex
L4       85771 LATEX

=> L3 and L4
L5        8477 L3 AND L4

=> particle
L6     1272932 PARTICLE

=> L5 and L6
L7        5662 L5 AND L6

=> copolymer
L8      636794 COPOLYMER

=> L8 and L4
L9       21732 L8 AND L4

=> L9 and L6
L10       6687 L9 AND L6

=> erythrocyte
L11     240675 ERYTHROCYTE

=> L11 and L1
L12        634 L11 AND L1

=> gelatiin
L13          0 GELATIIN

=> gelatin
L14      87313 GELATIN

=> L14 and L6
L15       7045 L14 AND L6

=> HCV
L16      32326 HCV

=> L16 and L7
L17          2 L16 AND L7

=> L16 and L9
L18          0 L16 AND L9

=> L16 and L10\
L19          0 L16 AND L10\

=> L16 and L10
```

```
L20           0 L16 AND L10

=> L16 and L12
L21           1 L16 AND L12

=> L16 and L15
L22           8 L16 AND L15

=> L16 and L1
L23         185 L16 AND L1

=> NS3 and L23
L24          34 NS3 AND L23

=> core and L24
L25          13 CORE AND L24

=> NS4 and L25
L26           8 NS4 AND L25

=> NS5 and L26
L27           6 NS5 AND L26

=> BSA and L27
L28           0 BSA AND L27

=> BSA
L29       26890 BSA

=> L29 and L24
L30           0 L29 AND L24

=> L29 and L23
L31           0 L29 AND L23

=> ovalbumin
L32       26826 OVALBUMIN

=> L32 and L23
L33           0 L32 AND L23

=> hemocyanin
L34       11251 HEMOCYANIN

=> L34 and L23
L35           1 L34 AND L23

=> D L21 IBIB ABS

L21  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1992:21470  CAPLUS
DOCUMENT NUMBER:          116:21470
TITLE:                    Synthetic peptide and reagent for analysis of
                          HCV (hepatitis C virus) antibodies using the
                          same
INVENTOR(S):              Hayashi, Nakanobu; Hashimoto, Masakatsu
PATENT ASSIGNEE(S):       Shima Kenkyusho Y. K., Japan
SOURCE:                   Jpn. Kokai Tokkyo Koho, 8 pp.
                          CODEN: JKXXAF
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     JP 03190898           A2    19910820    JP 1989-329746          19891221
PRIORITY APPLN. INFO.:                       JP 1989-329746          19891221
AB   A peptide having the common antigen determinant with HCV virus,
```

i.e. H-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-OH (I), is prepared by the **solid phase** method on Fmoc- or BOC-Leu-bound resin (Fmoc = 9H-fluoren-9-ylmethoxycarbonyl, BOC = Me3CO2C) using Fmoc-protected amino acids. A reagent for analyzing **HCV** antibodies by the latex agglutination turbidimetry or light scattering photometry comprises (A), a solid reagent (i.e. I immobilized through phys. absorption or chemical through spacers on a solid support such as a microtiter reaction plate, beads, a sheet, a porous membrane, or magnetic latex, more preferably (high-d.) latex particles, immobilized **erythrocyte**, gelatin particles, or immobilized bacteria) and (B) human globulin antibodies (e.g. human IgG or anti-human IgM) labeled with a radioisotope, enzyme, biotin, fluorescent dye, or Eu chelate or (C) a similarly labeled I. I of high purity can be prepared in large quantity at lower cost than the conventional **HCV**-derived antigen and is easily immobilized on the support and the immobilized I shows good reaction with the **HCV** antibodies of **HCV** patients with high sensitivity and specificity.

=> D L35 IBIB ABS

L35 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:37469 CAPLUS
DOCUMENT NUMBER: 118:37469
TITLE: Basic structural immunogenic polypeptides having epitopes for hepatitis C virus, antibodies, polynucleotide sequence, vaccines, and methods
INVENTOR(S): Kotwal, Girish J.; Baroudy, Bahige M.
PATENT ASSIGNEE(S): Gamble, James N., Institute of Medical Research, USA
SOURCE: PCT Int. Appl., 244 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9212992	A2	19920806	WO 1992-US356	19920114
WO 9212992	A3	19930318		
W: AT, AU, BG, BR, CA, CH, CS, DE, ES, FI, GB, HU, JP, KR, LU, NL, PL, RO, SE				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9214597	A1	19920827	AU 1992-14597	19920114
EP 571554	A1	19931201	EP 1992-907699	19920114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				

PRIORITY APPLN. INFO.: US 1991-639809 A 19910114
WO 1992-US356 A 19920114

AB Basic immunogenic peptides having epitopes for hepatitis C virus (**HCV**) are disclosed which are derived from the structural region of a human **HCV** genome. Preferred peptides are designated FGB1 and FGB2; sequences and characteristics are presented. Antibodies to the peptides, polynucleotide sequences encoding the peptides, vaccines containing the peptides, and immunoassay and nucleic acid hybridization assay methods, among others, are also disclosed. FGB1 and FGB2 were made by **solid-phase** synthesis and used in ELISAs to detect antibodies to **HCV** in blood and semen. DNA encoding FGB1 was cloned in recombinant vaccinia virus.

=> D L17 IBIB ABS 1-2

L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:610563 CAPLUS
DOCUMENT NUMBER: 131:241966
TITLE: Stabilization of hepatitis C virus antigen-sensitized **latex** reagent

INVENTOR(S): Taiheiraku, Yoshihiro; Ifuku, Yasuo; Miyoshi, Kinya; Washisu, Masayoshi
PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11258241	A2	19990924	JP 1998-56573	19980309
PRIORITY APPLN. INFO.:			JP 1998-56573	19980309

AB **Latex particles** sensitized with antigen or antibody is freeze-dried for stable long-term storage. Dispersing agent, stabilizer, carbohydrate, surfactant and antioxidant are added for stabilization of the immunoassay reagent. A test kit comprising such **latex particles** sensitized with hepatitis C virus antigen (especially C25 antigen) is provided for detecting **HCV**-specific antibody in blood plasma or serum samples.

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:253258 CAPLUS
DOCUMENT NUMBER: 118:253258
TITLE: Immunoassay for non-A non-B hepatitis using peptide epitopes of the capsid protein of hepatitis C virus
INVENTOR(S): Leahy, David C.; Todd, John A.; Jolley, Michael E.
PATENT ASSIGNEE(S): Baxter Diagnostics Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222571	A1	19921223	WO 1992-US3635	19920429
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2087974	AA	19921214	CA 1992-2087974	19920429
AU 9219720	A1	19930112	AU 1992-19720	19920429
AU 648912	B2	19940505		
EP 544861	A1	19930609	EP 1992-911917	19920429
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 06500796	T2	19940127	JP 1992-511153	19920429
JP 3350729	B2	20021125		
PRIORITY APPLN. INFO.:			US 1991-714471 A	19910613
			US 1991-718052 A	19910620
			WO 1992-US3635 A	19920429

AB The title assay uses synthetic peptides comprising the first 38 amino acids of the capsid region containing ≥2 immunodominant epitopes. The assay detects antibodies in the blood sera of patients infected with hepatitis C virus (**HCV**). Of particular efficacy is a competitive inhibition assay which incorporates in the liquid phase an inhibitor consisting of a peptide containing only 1 of the immunodominant capsid epitopes, which is capable of inhibiting binding of antibodies to all target epitopes present on the solid substrate. Peptide fragments of **HCV** capsid protein and derivs. of these peptides were coated onto paramagnetic **polystyrene** microparticles and tested against human **HCV** antiserum or plasma in a fluorescence enzyme immunoassay to identify immunodominant epitopes.

=> D L26 IBIB ABS 1-6

L26 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1130461 CAPLUS

DOCUMENT NUMBER: 143:385141
TITLE: Recombinant antigens (DS-**HCV**-antigens) for assay of antibodies to hepatitis C virus
INVENTOR(S): Burkov, A. N.; Obryadina, A. P.; Ulanova, T. I.; Gladysheva, M. V.
PATENT ASSIGNEE(S): Obshchestvo Ogranichennoi Otvetstvennost'yu Nauchno-Proizvodstvennoe Ob'edinenie "Diagnosticheskie Sistemy", Russia
SOURCE: Russ., 15 pp.
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2262704	C1	20051020	RU 2004-129264	20041006

PRIORITY APPLN. INFO.: RU 2004-129264 20041006

AB The disclosed invention proposes a set of recombinant antigens obtained on the basis of amino acid sequences of the most immunoreactive epitopes of hepatitis C virus proteins of different virus genotypes immobilized on surface of a **solid-phase** carrier. This set of recombinant antigens is used to develop an assay of antibodies raised against hepatitis C virus which is of higher sensitivity and specificity.

L26 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633152 CAPLUS
DOCUMENT NUMBER: 141:156083
TITLE: Simultaneous detection of **HCV** antigen and anti-**HCV** antibodies in combination assay or sole antibody assay
INVENTOR(S): Shah, Dinesh O.; Cheng, Yu; Stewart, James L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152070	A1	20040805	US 2003-357816	20030204
CA 2515084	AA	20040819	CA 2004-2515084	20040203
WO 2004070387	A1	20040819	WO 2004-US3076	20040203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1590671	A1	20051102	EP 2004-707764	20040203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-357816 A 20030204
WO 2004-US3076 W 20040203

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Such methods may be carried out in the presence of a diluent comprising a reductant or lacking a reductant. Furthermore, the performance of such methods may be maximized by altering such variables as the nature of the antigen coated on the **solid phase**, temperature application and time. The **HCV** antigens are **core** antigen, **NS3**, **NS4**, NS5 and fragments.
The method comprises formation of antigen-antibody complexes, addition of chemiluminescent compound-labeled antibody to bind the antigen-antibody

complexes, and measuring the chemiluminescent signal.

L26 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633162 CAPLUS
DOCUMENT NUMBER: 139:178676
TITLE: Methods for the simultaneous detection of **hcv** antigens and **hcv** antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:
US 2001-891983 A2 20010626
US 2002-173480 A 20020617
WO 2002-US19958 W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L26 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:509788 CAPLUS
DOCUMENT NUMBER: 139:67449
TITLE: Comparative study of peptide antigens and polymer surface interactions. The influence on sensitivity and specificity in serodiagnosis of **HCV** and HIV
AUTHOR(S): Burov, Sergey; Leko, Maria; Glinskaya, Oxana; Shkarubskaya, Zoya; Kharina, Maria; Dorosh, Marina; Lisok, Tamara; Mobarhan, Asadi
CORPORATE SOURCE: Institute of Macromolecular Compounds, Academy of Sciences, St.-Petersburg, Russia
SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 865-866. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4
DOCUMENT TYPE: Conference
LANGUAGE: English

AB The determination of specific antibodies against distinct antigenic proteins of a given pathogen is the most commonly used diagnostic tool for the detection of viral infections. Although a large number of the established test systems still use natural antigens from different sources, synthetic peptides, representing the specific antigenic determinants possess the significant advantages. However, the interaction of peptides with the polymer surface may have appreciable influence on the efficiency of their application in ELISA test systems. Apart from induced conformational changes there are significant difference in attachment of polypeptides to the **solid phase** and possible competition for the correspondent binding sites. Thus, quant. control of the antigenic determinants adsorption process may represent a useful tool for the enhancement of ELISA diagnostic system sensitivity.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:23040 CAPLUS
DOCUMENT NUMBER: 138:88633
TITLE: Methods for the simultaneous detection of **HCV** antigens and **HCV** antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George A.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2003108858	A1	20030612	US 2001-891983	20010626
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
CA 2450710	AA	20030109	CA 2002-2450710	20020624
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624

PRIORITY APPLN. INFO.:
US 2001-891983 A 20010626
US 2002-173480 A 20020617
WO 2002-US19958 W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply.

L26 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:298250 CAPLUS
DOCUMENT NUMBER: 131:127333
TITLE: Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection
AUTHOR(S): Chien, David Y.; Arcangel, Phillip; Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark; Nguyen,

Steve; George-Nascimento, Carlos; Gyenes, Alexander; Kuo, George; Valenzuela, Pablo
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94507, USA
SOURCE: Journal of Clinical Microbiology (1999), 37(5), 1393-1397
CODEN: JCMIDW; ISSN: 0095-1137
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The genome of hepatitis C virus (**HCV**) consists of seven functional regions: the **core**, E1, E2/NS1, NS2, **NS3**, **NS4**, and NS5 regions. The U.S. Food and Drug Administration-licensed 2.0G immunoassay for the detection of anti-**HCV** uses proteins from the **core**, **NS3**, and **NS4** regions. The 3.0G ELISA includes the protein from the NS5 region. The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different genotype samples has been demonstrated previously. In this study we have attempted to improve the sensitivity of the anti-**HCV** assay by developing a single multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of the major immunodominant epitopes from the seven functional regions of the **HCV** genome. A nucleic acid sequence consisting of proteins from the viral **core**, E1, E2, **NS3**, **NS4**, and NS5 regions and different subtype-specific regions of the **NS4** region was constructed, cloned, and expressed in yeast. The epitopes present on this antigen can be detected by epitope-specific monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6 protein competed with 83 to 96% of genotype-specific antibodies from **HCV** genotype-specific peptides. This recombinant antigen was subsequently used to design an anti-**HCV** chemiluminescent immunoassay. We designed our assay using a monoclonal anti-human IgG antibody bound to the **solid phase**. Because MEFA-6 is fused with human superoxide dismutase (h-SOD), we used an anti-human superoxide dismutase, di-Me acridinium ester-labeled monoclonal antibody for detection. Our results indicate that MEFA-6 exposes all of the major immunogenic epitopes. Its excellent sensitivity and specificity for the detection of clin. seroconversion are demonstrated by this assay.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D L27 IBIB ABS 1-6

L27 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1130461 CAPLUS
DOCUMENT NUMBER: 143:385141
TITLE: Recombinant antigens (DS-**HCV**-antigens) for assay of antibodies to hepatitis C virus
INVENTOR(S): Burkov, A. N.; Obryadina, A. P.; Ulanova, T. I.; Gladysheva, M. V.
PATENT ASSIGNEE(S): Obshchestvo Ogranichennoi Otvetstvennost'yu Nauchno-Proizvodstvennoe Ob'edinenie "Diagnosticheskie Sistemy", Russia
SOURCE: Russ., 15 pp.
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2262704	C1	20051020	RU 2004-129264	20041006

PRIORITY APPLN. INFO.: RU 2004-129264 20041006

AB The disclosed invention proposes a set of recombinant antigens obtained on the basis of amino acid sequences of the most immunoreactive epitopes of hepatitis C virus proteins of different virus genotypes immobilized on surface of a **solid-phase** carrier. This set of recombinant antigens is used to develop an assay of antibodies raised

against hepatitis C virus which is of higher sensitivity and specificity.

L27 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633152 CAPLUS
DOCUMENT NUMBER: 141:156083
TITLE: Simultaneous detection of **HCV** antigen and anti-**HCV** antibodies in combination assay or sole antibody assay
INVENTOR(S): Shah, Dinesh O.; Cheng, Yu; Stewart, James L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152070	A1	20040805	US 2003-357816	20030204
CA 2515084	AA	20040819	CA 2004-2515084	20040203
WO 2004070387	A1	20040819	WO 2004-US3076	20040203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1590671	A1	20051102	EP 2004-707764	20040203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-357816 A 20030204
WO 2004-US3076 W 20040203

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Such methods may be carried out in the presence of a diluent comprising a reductant or lacking a reductant. Furthermore, the performance of such methods may be maximized by altering such variables as the nature of the antigen coated on the **solid phase**, temperature application and time. The **HCV** antigens are **core** antigen, **NS3**, **NS4**, **NS5** and fragments. The method comprises formation of antigen-antibody complexes, addition of chemiluminescent compound-labeled antibody to bind the antigen-antibody complexes, and measuring the chemiluminescent signal.

L27 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633162 CAPLUS
DOCUMENT NUMBER: 139:178676
TITLE: Methods for the simultaneous detection of **hcv** antigens and **hcv** antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626

CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		
PRIORITY APPLN. INFO.:			US 2001-891983 A2	20010626
			US 2002-173480 A	20020617
			WO 2002-US19958 W	20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L27 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:23040 CAPLUS
DOCUMENT NUMBER: 138:88633
TITLE: Methods for the simultaneous detection of **HCV** antigens and **HCV** antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George A.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2003108858	A1	20030612	US 2001-891983	20010626
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
CA 2450710	AA	20030109	CA 2002-2450710	20020624
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
PRIORITY APPLN. INFO.:			US 2001-891983 A	20010626
			US 2002-173480 A	20020617
			WO 2002-US19958 W	20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety

of the blood supply.

L27 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:298250 CAPLUS
DOCUMENT NUMBER: 131:127333
TITLE: Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection
AUTHOR(S): Chien, David Y.; Arcangel, Phillip; Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark; Nguyen, Steve; George-Nascimento, Carlos; Gyenes, Alexander; Kuo, George; Valenzuela, Pablo
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94507, USA
SOURCE: Journal of Clinical Microbiology (1999), 37(5), 1393-1397
CODEN: JCMIDW; ISSN: 0095-1137
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The genome of hepatitis C virus (**HCV**) consists of seven functional regions: the **core**, E1, E2/NS1, NS2, **NS3**, **NS4**, and **NS5** regions. The U.S. Food and Drug Administration-licensed 2.0G immunoassay for the detection of anti-**HCV** uses proteins from the **core**, **NS3**, and **NS4** regions. The 3.0G ELISA includes the protein from the **NS5** region. The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different genotype samples has been demonstrated previously. In this study we have attempted to improve the sensitivity of the anti-**HCV** assay by developing a single multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of the major immunodominant epitopes from the seven functional regions of the **HCV** genome. A nucleic acid sequence consisting of proteins from the viral **core**, E1, E2, **NS3**, **NS4**, and **NS5** regions and different subtype-specific regions of the **NS4** region was constructed, cloned, and expressed in yeast. The epitopes present on this antigen can be detected by epitope-specific monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6 protein competed with 83 to 96% of genotype-specific antibodies from **HCV** genotype-specific peptides. This recombinant antigen was subsequently used to design an anti-**HCV** chemiluminescent immunoassay. We designed our assay using a monoclonal anti-human IgG antibody bound to the **solid phase**. Because MEFA-6 is fused with human superoxide dismutase (h-SOD), we used an anti-human superoxide dismutase, di-Me acridinium ester-labeled monoclonal antibody for detection. Our results indicate that MEFA-6 exposes all of the major immunogenic epitopes. Its excellent sensitivity and specificity for the detection of clin. seroconversion are demonstrated by this assay.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:241608 BIOSIS
DOCUMENT NUMBER: PREV199900241608
TITLE: Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection.
AUTHOR(S): Chien, David Y. [Reprint author]; Arcangel, Phillip; Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark; Nguyen, Steve; George-Nascimento, Carlos; Gyenes, Alexander; Kuo, George; Valenzuela, Pablo
CORPORATE SOURCE: Life Science Center 4.302, Chiron Corporation, 4560 Horton St., Emeryville, CA, 94507, USA
SOURCE: Journal of Clinical Microbiology, (May, 1999) Vol. 37, No. 5, pp. 1393-1397. print.
CODEN: JCMIDW. ISSN: 0095-1137.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Jun 1999
Last Updated on STN: 17 Jun 1999

AB The genome of hepatitis C virus (**HCV**) consists of seven functional regions: the **core**, E1, E2/NS1, NS2, **NS3**, **NS4**, and **NS5** regions. The U.S. Food and Drug Administration-licensed 2.0G immunoassay for the detection of anti-**HCV** uses proteins from the **core**, **NS3**, and **NS4** regions (McHutchinson et al., Hepatology 15:19-25, 1992). The 3.0G enzyme-linked immunosorbent assay includes the protein from the **NS5** region (Uyttendaele et al., Vox Sang. 66:122-129, 1994). The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different genotype samples has been demonstrated previously (Chien et al., Lancet 342:933, 1993; Lok et al., Hepatology 18:497-502, 1993). In this study we have attempted to improve the sensitivity of the anti-**HCV** assay by developing a single multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of the major immunodominant epitopes from the seven functional regions of the **HCV** genome. A nucleic acid sequence consisting of proteins from the viral **core**, E1, E2, **NS3**, **NS4**, and **NS5** regions and different subtype-specific regions of the **NS4** region was constructed, cloned, and expressed in yeast. The epitopes present on this antigen can be detected by epitope-specific monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6 protein competed with 83 to 96% of genotype-specific antibodies from **HCV** genotype-specific peptides. This recombinant antigen was subsequently used to design an anti-**HCV** chemiluminescent immunoassay. We designed our assay using a monoclonal anti-human immunoglobulin G antibody bound to the **solid phase**. Because MEFA-6 is fused with human superoxide dismutase (h-SOD), we used an anti-human superoxide dismutase, dimethyl acridinium ester-labeled monoclonal antibody for detection. Our results indicate that MEFA-6 exposes all of the major immunogenic epitopes. Its excellent sensitivity and specificity for the detection of clinical seroconversion are demonstrated by this assay.

=> D L22 IBIB ABS 1-8

L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:644976 CAPLUS
DOCUMENT NUMBER: 137:165835
TITLE: Virus nucleic acid isolation via surface binding and surfactant release and PCR amplification
INVENTOR(S): Murata, Mitsuhiro; Fan, Ke-Chun; Higata, Mikio; Sato, Koei; Yamaguchi, Teruhide
PATENT ASSIGNEE(S): JSR Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002238565	A2	20020827	JP 2001-35066	20010213

PRIORITY APPLN. INFO.: JP 2001-35066 20010213

AB This invention provides a method of isolation of nucleic acid from virus by binding of virus to a water insol. support and separation of nucleic acid using a surfactant and amplification via PCR. A glass or magnetic **particle** support containing a virus-binding substance such as antibodies to virus surface antigen, lectin, or glycoconjugate, are used. An anionic surfactant or a steroid-containing surfactant is used in combination with albumin or **gelatin**. Isolation of HBV using an anti-HBs antibody immobilized glass beads, deoxycholic acid, and BSA, and isolation of **HCV** using a Ricin A chain immobilized magnetic **particles**, and sodium N-lauroyl sarcosinate, and RT-PCR amplification are described.

L22 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:498585 CAPLUS
DOCUMENT NUMBER: 131:167375

TITLE: Superoxide dismutase fusion protein-binding reagent as absorbent to remove nonspecific reaction in immunoassay
INVENTOR(S): Kawado, Katsuhito; Nakamura, Masato
PATENT ASSIGNEE(S): Fujirebio, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11218534	A2	19990810	JP 1998-32372	19980130
JP 3520757	B2	20040419		

PRIORITY APPLN. INFO.: JP 1998-32372 19980130
OTHER SOURCE(S): MARPAT 131:167375

AB Aminocarboxylic acids, e.g. ε-aminocaproic acid, p-(aminomethyl)cyclohexanecarboxylic acid and lysine, are provided as absorbent for immunoassay to reduce nonspecific binding of superoxide dismutase-antigen fusion protein. Thus, fusion protein comprising superoxide dismutase and hepatitis C virus core antigen C200 protein was prepared by mol. cloning and coated on **gelatin particles** for immunoassay of anti-**HCV** antibody in serum sample in the presence of above mentioned aminocarboxylic acids.

L22 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:554170 CAPLUS
DOCUMENT NUMBER: 129:310488
TITLE: Plasma hydroxy metronidazole/metronidazole ratio in anti-**HCV** carriers with and without apparent liver disease
AUTHOR(S): Da Silva, C. M. F.; David, F. L.; Muscara, M. N.; Sousa, S. S.; Ferraz, J. G. P.; De Nucci, G.; Polimeno, N. C.; Pedrazzoli, J., Jr.
CORPORATE SOURCE: Clinical Pharmacology Unit, Sao Francisco University Medical School, Braganca Paulista, 218 12900-000, Brazil
SOURCE: British Journal of Clinical Pharmacology (1998), 46(2), 176-180
CODEN: BCPHBM; ISSN: 0306-5251
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Our objective was to evaluate plasma hydroxy-metronidazole/metronidazole ratio as a dynamic liver function test in **HCV**-infected individuals with/without liver disease, in the absence of liver cirrhosis. Metronidazole was administered i.v. in healthy volunteers, asymptomatic anti-**HCV**-pos. blood donors, and in chronic hepatitis C patients. Serol. to **HCV** was determined by a second generation assay and confirmed by **gelatin particle** agglutination test using recombinant antigens C22-3 and C200. Plasma concentration of metronidazole and hydroxy-metronidazole was measured by high performance liquid chromatog. in samples collected 5, 10, 20 and 30 min following the end of metronidazole infusion. Chronic hepatitis C patients had abnormal liver enzymes, while healthy volunteers and anti-**HCV**-pos. blood donors had normal liver biochem. tests. Plasma metronidazole concentration was similar in all groups studied. Plasma hydroxy-metronidazole/metronidazole ratio was significantly reduced in **HCV**-infected subjects, an effect observed 10 min after the end of drug infusion. Metronidazole clearance is impaired in anti-**HCV**-pos. blood donors and chronic hepatitis C patients, indicating that **HCV** is capable of affecting liver function at early stages of the disease. The metronidazole clearance test can detect impaired liver function in **HCV**-infected individuals even in the absence of liver cirrhosis.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:625871 CAPLUS
DOCUMENT NUMBER: 121:225871
TITLE: Immunoassay with solid support-immobilized and magnetic **particle**-immobilized same antigen
INVENTOR(S): Kaneko, Yasunobu
PATENT ASSIGNEE(S): Olympus Optical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06186231	A2	19940708	JP 1992-341808	19921222
PRIORITY APPLN. INFO.:			JP 1992-341808	19921222

AB The title method uses an immobilized antigen on the inner wall of a reaction chamber and an immobilized same antigen on a magnetic carrier **particle** (e.g. **gelatin**). Thus, for determination of anti-hepatitis C virus (**HCV**) antibody, **HCV** core antigen was immobilized on the well bottom of a plate and sep. on **gelatin particle**. Use of the magnetic **particle** -immobilized **HCV** core antigen exhibited higher sensitivity than with a magnetic **particle**-immobilized anti-human IgG antibody.

L22 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:21470 CAPLUS
DOCUMENT NUMBER: 116:21470
TITLE: Synthetic peptide and reagent for analysis of **HCV** (hepatitis C virus) antibodies using the same
INVENTOR(S): Hayashi, Nakanobu; Hashimoto, Masakatsu
PATENT ASSIGNEE(S): Shima Kenkyusho Y. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03190898	A2	19910820	JP 1989-329746	19891221
PRIORITY APPLN. INFO.:			JP 1989-329746	19891221

AB A peptide having the common antigen determinant with **HCV** virus, i.e. H-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-OH (I), is prepared by the solid phase method on Fmoc- or BOC-Leu-bound resin (Fmoc = 9H-fluoren-9-ylmethoxycarbonyl, BOC = Me3CO2C) using Fmoc-protected amino acids. A reagent for analyzing **HCV** antibodies by the latex agglutination turbidimetry or light scattering photometry comprises (A), a solid reagent (i.e. I immobilized through phys. absorption or chemical through spacers on a solid support such as a microtiter reaction plate, beads, a sheet, a porous membrane, or magnetic latex, more preferably (high-d.) latex **particles**, immobilized erythrocyte, **gelatin particles**, or immobilized bacteria) and (B) human globulin antibodies (e.g. human IgG or anti-human IgM) labeled with a radioisotope, enzyme, biotin, fluorescent dye, or Eu chelate or (C) a similarly labeled I. I of high purity can be prepared in large quantity at lower cost than the conventional **HCV** -derived antigen and is easily immobilized on the support and the immobilized I shows good reaction with the **HCV** antibodies of **HCV** patients with high sensitivity and specificity.

L22 ANSWER 6 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:30922 BIOSIS
DOCUMENT NUMBER: PREV200300030922

TITLE: Transfusion transmissible infections (TTI) markers development over an eight-year period in a hospital blood bank in Argentina.
AUTHOR(S): Remesar, M. [Reprint Author]; Oknaian, S. [Reprint Author]; del Pozo, A. [Reprint Author]
CORPORATE SOURCE: Servicio de Hemoterapia, Hospital de Pediatria Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina
SOURCE: Vox Sanguinis, (August 2002) Vol. 83, No. Supplement 2, pp. 195-196. print.
Meeting Info.: 27th Congress of the International Society of Blood Transfusion held in conjunction with Canadian Society of Transfusion Medicine. Vancouver, British Colombia, Canada. August 24-29, 2002. International Society of Blood Transfusion; Canadian Society of Transfusion Medicine.
ISSN: 0042-9007 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jan 2003
Last Updated on STN: 8 Jan 2003

L22 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1998:401913 BIOSIS
DOCUMENT NUMBER: PREV199800401913
TITLE: Plasma hydroxy metronidazole/metronidazole ration in anti-**HCV** carriers with and without apparent liver disease.
AUTHOR(S): da Silva, C. M. F.; David, F. L.; Muscara, M. N.; Sousa, S. S.; Ferraz, J. G. P.; De Nucci, G.; Polimeno, N. C.; Pedrazzoli, J., Jr. [Reprint author]
CORPORATE SOURCE: Clin. Pharmacol. Unit, Sao Francisco Univ. Med. Sch., Av. Sao Francisco de Assis, 218 12900-000, Braganca Paulista, SP, Brazil
SOURCE: British Journal of Clinical Pharmacology, (Aug., 1998) Vol. 46, No. 2, pp. 176-180. print.
CODEN: BCPHBM. ISSN: 0306-5251.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 21 Sep 1998
Last Updated on STN: 21 Sep 1998
AB Aims: To evaluate plasma hydroxy-metronidazole/metronidazole ratio as a dynamic liver function test in **HCV**-infected individuals with/without liver disease, in the absence of liver cirrhosis. Methods: Metronidazole was administered intravenously in healthy volunteers, asymptomatic anti-**HCV**-positive blood donors, and in chronic hepatitis C patients. Serology to **HCV** was determined by a second generation assay and confirmed by **gelatin particle** agglutination test using recombinant antigens C22-3 and C200. Plasma concentration of metronidazole and hydroxy-metronidazole was measured by high performance liquid chromatography in samples collected 5, 10, 20 and 30 min following the end of metronidazole infusion. Results: Chronic hepatitis C patients had abnormal liver enzymes, while healthy volunteers and anti-**HCV**-positive blood donors had normal liver biochemistry tests. Plasma metronidazole concentration was similar in all groups studied. Plasma hydroxy-metronidazole/metronidazole ratio was significantly reduced in **HCV**-infected subjects, an effect observed 10 min after the end of drug infusion. Conclusions: Metronidazole clearance is impaired in anti-**HCV**-positive blood donors and chronic hepatitis C patients, indicating that **HCV** is capable of affecting liver function at early stages of the disease. The metronidazole clearance test can detect impaired liver function in **HCV**-infected individuals even in the absence of liver cirrhosis.

L22 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1996:395811 BIOSIS
DOCUMENT NUMBER: PREV199699118167
TITLE: Characterization of the low titer group of anti-**HCV** positive donors determined by **gelatin**

particle agglutination test.
AUTHOR(S): Awakihara, Shuji; Naoki, Kyoko; Miyahara, Masayuki; Sato, Hiromasa
CORPORATE SOURCE: Japanese Red Cross Okayama Blood Center, Okayama, Japan
SOURCE: Vox Sanguinis, (1996) Vol. 70, No. SUPPL. 2, pp. 147.
Meeting Info.: 24th Congress of the International Society of Blood Transfusion. Makuhari Messe, Japan. March 31-April 5, 1996.
CODEN: VOSAAD. ISSN: 0042-9007.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Sep 1996
Last Updated on STN: 3 Sep 1996

=> D L24 IBIB TI 1-34

L24 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1130461 CAPLUS
DOCUMENT NUMBER: 143:385141
TITLE: Recombinant antigens (DS-**HCV**-antigens) for assay of antibodies to hepatitis C virus
INVENTOR(S): Burkov, A. N.; Obryadina, A. P.; Ulanova, T. I.; Gladysheva, M. V.
PATENT ASSIGNEE(S): Obshchestvo Ogranichennoi Otvetstvennost'yu Nauchno-Proizvodstvennoe Ob'edinenie "Diagnosticheskie Sistemy", Russia
SOURCE: Russ., 15 pp.
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2262704	C1	20051020	RU 2004-129264	20041006

PRIORITY APPLN. INFO.: RU 2004-129264 20041006
TI Recombinant antigens (DS-**HCV**-antigens) for assay of antibodies to hepatitis C virus

L24 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633152 CAPLUS
DOCUMENT NUMBER: 141:156083
TITLE: Simultaneous detection of **HCV** antigen and anti-**HCV** antibodies in combination assay or sole antibody assay
INVENTOR(S): Shah, Dinesh O.; Cheng, Yu; Stewart, James L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152070	A1	20040805	US 2003-357816	20030204
CA 2515084	AA	20040819	CA 2004-2515084	20040203
WO 2004070387	A1	20040819	WO 2004-US3076	20040203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,

MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1590671 A1 20051102 EP 2004-707764 20040203

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2003-357816 A 20030204

WO 2004-US3076 W 20040203

TI Simultaneous detection of **HCV** antigen and anti-**HCV** antibodies in combination assay or sole antibody assay

L24 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:912843 CAPLUS

DOCUMENT NUMBER: 139:381756

TITLE: Preparation of peptides as **NS3**-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; Mccormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 629 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003216325	A1	20031120	US 2001-908955	20010719
US 2004254117	A9	20041216		
CN 1498224	A	20040519	CN 2001-813111	20010719
ZA 2002010312	A	20040329	ZA 2002-10312	20021219

PRIORITY APPLN. INFO.: US 2000-220108P P 20000721

OTHER SOURCE(S): MARPAT 139:381756

TI Preparation of peptides as **NS3**-serine protease inhibitors of hepatitis C virus

L24 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:634705 CAPLUS

TITLE: **Solid phase** parallel synthesis of alpha-ketoamide inhibitors of **NS3**-4A **HCV** Protease

AUTHOR(S): Court, John J.; Cottrell, Kevin C.; Harbeson, Scott L.; Pitlik, Janos

CORPORATE SOURCE: Department of Medicinal Chemistry, Vertex Pharmaceuticals Inc, Cambridge, MA, 02139, USA

SOURCE: Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), MEDI-097. American Chemical Society: Washington, D. C.
CODEN: 69EKY9

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

TI **Solid phase** parallel synthesis of alpha-ketoamide inhibitors of **NS3**-4A **HCV** Protease

L24 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:633162 CAPLUS

DOCUMENT NUMBER: 139:178676

TITLE: Methods for the simultaneous detection of **hcv** antigens and **hcv** antibodies

INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A.

Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:
US 2001-891983 A2 20010626
US 2002-173480 A 20020617
WO 2002-US19958 W 20020624

TI Methods for the simultaneous detection of **hcv** antigens and **hcv** antibodies

L24 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:509788 CAPLUS
DOCUMENT NUMBER: 139:67449
TITLE: Comparative study of peptide antigens and polymer surface interactions. The influence on sensitivity and specificity in serodiagnosis of **HCV** and HIV
AUTHOR(S): Burov, Sergey; Leko, Maria; Glinskaya, Oxana; Shkarubskaya, Zoya; Kharina, Maria; Dorosh, Marina; Lisok, Tamara; Mobarhan, Asadi
CORPORATE SOURCE: Institute of Macromolecular Compounds, Academy of Sciences, St.-Petersburg, Russia
SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 865-866. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.
CODEN: 69EDWK; ISBN: 2-84254-048-4
DOCUMENT TYPE: Conference
LANGUAGE: English
TI Comparative study of peptide antigens and polymer surface interactions. The influence on sensitivity and specificity in serodiagnosis of **HCV** and HIV
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:393701 CAPLUS
DOCUMENT NUMBER: 139:381715
TITLE: Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length **NS3** (Protease-Helicase/NTPase): a comparative study of different C-terminals
AUTHOR(S): Johansson, Anja; Poliakov, Anton; Akerblom, Eva; Wiklund, Karin; Lindeberg, Gunnar; Winiwarter, Susanne; Danielson, U. Helena; Samuelsson, Bertil;

Hallberg, Anders
CORPORATE SOURCE: BMC, Department of Medicinal Chemistry, Uppsala University, Uppsala, SE-751 23, Swed.
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(12), 2551-2568
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:381715
TI Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length **NS3** (Protease-Helicase/NTPase): a comparative study of different C-terminals
REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:23040 CAPLUS
DOCUMENT NUMBER: 138:88633
TITLE: Methods for the simultaneous detection of **HCV** antigens and **HCV** antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George A.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2003108858	A1	20030612	US 2001-891983	20010626
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
CA 2450710	AA	20030109	CA 2002-2450710	20020624
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624

PRIORITY APPLN. INFO.:
US 2001-891983 A 20010626
US 2002-173480 A 20020617
WO 2002-US19958 W 20020624

TI Methods for the simultaneous detection of **HCV** antigens and **HCV** antibodies

L24 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:777963 CAPLUS
DOCUMENT NUMBER: 137:295254
TITLE: Preparation of peptide inhibitors of hepatitis C virus **NS3** protease
INVENTOR(S): Colarusso, Stefania; Gardelli, Cristina; Gerlach, Benjamin; Harper, Steven; Koch, Uwe; Matassa, Victor Giulio; Muraglia, Ester; Narjes, Frank; Ontoria, Ontoria Jesus Maria; Petrocchi, Alessia; Ponzi, Simona; Stansfield, Ian; Summa, Vincenzo
PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P. Angeletti Spa, Italy; et al.
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002079234	A1	20021010	WO 2002-EP3435		20020326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2442540	AA	20021010	CA 2002-2442540		20020326
EP 1392721	A1	20040303	EP 2002-757728		20020326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 2004142876	A1	20040722	US 2004-473443		20040303
PRIORITY APPLN. INFO.:			GB 2001-7924	A	20010329
			WO 2002-EP3435	W	20020326

OTHER SOURCE(S): MARPAT 137:295254
TI Preparation of peptide inhibitors of hepatitis C virus **NS3** protease
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:692477 CAPLUS
DOCUMENT NUMBER: 138:369163
TITLE: Different types of P1 residues in peptide-based inhibitors of hepatitis C virus full-length **NS3** protease
AUTHOR(S): Johansson, Anja; Akerblom, Eva; Lindeberg, Gunnar; Poliakov, Anton; Danielsson, U. Helena; Hallberg, Anders
CORPORATE SOURCE: Department of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, SE-751 23, Swed.
SOURCE: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 549-550. Editor(s): Lebl, Michal; Houghten, Richard A. American Peptide Society: San Diego, Calif.
CODEN: 69DBAL; ISBN: 0-9715560-0-8
DOCUMENT TYPE: Conference
LANGUAGE: English
TI Different types of P1 residues in peptide-based inhibitors of hepatitis C virus full-length **NS3** protease
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:116966 CAPLUS
DOCUMENT NUMBER: 137:125377
TITLE: Solution and **solid-Phase** synthesis of potent inhibitors of hepatitis C Virus **NS3** proteinase
AUTHOR(S): Beevers, Rebekah; Carr, Maria G.; Jones, Philip S.; Jordan, Steven; Kay, Paul B.; Lazell, Robert C.; Raynham, Tony M.
CORPORATE SOURCE: Department of Chemistry, Roche Discovery Welwyn, Hertfordshire, Welwyn Garden City, AL7 3AY, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 641-643
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:125377
TI Solution and **solid-Phase** synthesis of potent inhibitors of hepatitis C Virus **NS3** proteinase
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:90007 CAPLUS
DOCUMENT NUMBER: 136:151439
TITLE: Preparation of novel peptides as **NS3**-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu, Zhaoning; Arasappan, Ashok; Chen, Kevin X.; Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam, Bama; Njoroge, F. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2410682	AA	20020131	CA 2001-2410682	20010719
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012666	A	20030610	BR 2001-12666	20010719
JP 2004513881	T2	20040513	JP 2002-514094	20010719
NZ 523781	A	20041029	NZ 2001-523781	20010719
ZA 2002010311	A	20040319	ZA 2002-10311	20021219
NO 2003000271	A	20030318	NO 2003-271	20030120
US 2005176648	A1	20050811	US 2005-89192	20050324

PRIORITY APPLN. INFO.:	US 2000-220107P	P	20000721
	US 2001-909012	A3	20010719
	WO 2001-US22813	W	20010719

OTHER SOURCE(S): MARPAT 136:151439
TI Preparation of novel peptides as **NS3**-serine protease inhibitors of hepatitis C virus
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:864881 CAPLUS
DOCUMENT NUMBER: 136:4700
TITLE: Method for preparing antigen-bound **solid phase** carrier
INVENTOR(S): Sakagami, Naohito; Yamamoto, Katsuhiko
PATENT ASSIGNEE(S): Fujirebio, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001330616	A2	20011130	JP 2000-149215	20000522

PRIORITY APPLN. INFO.: JP 2000-149215 20000522
TI Method for preparing antigen-bound **solid phase** carrier

L24 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:435622 CAPLUS
DOCUMENT NUMBER: 135:195782
TITLE: **Solid-Phase** Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus **NS3** Protease
AUTHOR(S): Poupart, Marc-Andre; Cameron, Dale R.; Chabot, Catherine; Ghiro, Elise; Goudreau, Nathalie; Goulet, Sylvie; Poirier, Martin; Tsantrizos, Youla S.
CORPORATE SOURCE: Department of Chemistry, Boehringer Ingelheim (Canada) Ltd., QC, H7S 2G5, Can.
SOURCE: Journal of Organic Chemistry (2001), 66(14), 4743-4751
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:195782
TI **Solid-Phase** Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus **NS3** Protease
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:338559 CAPLUS
DOCUMENT NUMBER: 134:340710
TITLE: Preparation of peptides as **HCV NS3** protease inhibitors
INVENTOR(S): Fattori, Daniela; Pessi, Antonello; Ingallinella, Paolo; Bianchi, Elisabetta
PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy; Nicholls, Kathryn, M.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032691	A1	20010510	WO 2000-GB4195	20001102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2389543	AA	20010510	CA 2000-2389543	20001102
EP 1230260	A1	20020814	EP 2000-973007	20001102
EP 1230260	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003513891	T2	20030415	JP 2001-535390	20001102

AT 250080	E	20031015	AT 2000-973007		20001102
ES 2204713	T3	20040501	ES 2000-973007		20001102
AU 780100	B2	20050303	AU 2001-11564		20001102
PRIORITY APPLN. INFO.:			GB 1999-25955	A	19991102
			WO 2000-GB4195	W	20001102

OTHER SOURCE(S): MARPAT 134:340710
TI Preparation of peptides as **HCV NS3** protease inhibitors
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:97717 CAPLUS
DOCUMENT NUMBER: 132:293998
TITLE: **Solid phase** synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein
AUTHOR(S): Ede, Nicholas J.; Eagle, Susan N.; Wickham, Geoffrey; Bray, Andrew M.; Warne, Bob; Shoemaker, Kevin; Rosenberg, Steve
CORPORATE SOURCE: Chiron Technologies Pty. Ltd., Clayton, 3168, Australia
SOURCE: Journal of Peptide Science (2000), 6(1), 11-18
CODEN: JPSIEI; ISSN: 1075-2617
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:293998
TI **Solid phase** synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:810845 CAPLUS
DOCUMENT NUMBER: 132:117137
TITLE: A loop-mimetic inhibitor of the **HCV-NS3** protease derived from a minibody
AUTHOR(S): Martin, F.; Steinkuhler, C.; Brunetti, M.; Pessi, A.; Cortese, R.; De Francesco, R.; Sollazzo, M.
CORPORATE SOURCE: Istituto di Ricerche di Biologia Molecolare (IRBM) P. Angeletti, Rome, 600-00040, Italy
SOURCE: Protein Engineering (1999), 12(11), 1005-1011
CODEN: PRENE9; ISSN: 0269-2139
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
TI A loop-mimetic inhibitor of the **HCV-NS3** protease derived from a minibody
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:691299 CAPLUS
DOCUMENT NUMBER: 131:335784
TITLE: Preparation of recombinant **HCV NS3** antigen and immobilization of the antigen in the presence of reducing agent for immunodiagnostic assay
INVENTOR(S): Maertens, Geert; Louwagie, Joost; Bosman, Alfons; Sablon, Erwin; Zrein, Maan
PATENT ASSIGNEE(S): Innogenetics N.V., Belg.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9954735 A1 19991028 WO 1999-EP2547 19990415
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2324970 AA 19991028 CA 1999-2324970 19990415
AU 9938171 A1 19991108 AU 1999-38171 19990415
AU 751362 B2 20020815
BR 9909678 A 20001219 BR 1999-9678 19990415
TR 200003024 T2 20001221 TR 2000-200003024 19990415
EP 1071955 A1 20010131 EP 1999-920678 19990415
EP 1071955 B1 20041006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2002512370 T2 20020423 JP 2000-545027 19990415
TR 200101647 T2 20020621 TR 2001-200101647 19990415
TR 200101648 T2 20020621 TR 2001-200101648 19990415
TR 200202213 T2 20021121 TR 2002-200202213 19990415
AT 278960 E 20041015 AT 1999-920678 19990415
EP 1471074 A2 20041027 EP 2004-103238 19990415
EP 1471074 A3 20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY
PT 1071955 T 20050228 PT 1999-920678 19990415
ES 2230851 T3 20050501 ES 1999-920678 19990415
ZA 2000005445 A 20030106 ZA 2000-5445 20001005
HK 1036653 A1 20050408 HK 2001-105349 20010731
JP 2005185285 A2 20050714 JP 2005-767 20050105
PRIORITY APPLN. INFO.: EP 1998-870087 A 19980417
EP 1999-920678 A3 19990415
JP 2000-545027 A3 19990415
WO 1999-EP2547 W 19990415

TI Preparation of recombinant **HCV NS3** antigen and immobilization of the antigen in the presence of reducing agent for immunodiagnostic assay

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:640820 CAPLUS
DOCUMENT NUMBER: 131:257878
TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus **NS3** protease
INVENTOR(S): Tung, Roger D.; Farmer, Luc J.; Bhisetti, Govinda R.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950230	A1	19991007	WO 1999-US7149	19990331

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9933766	A1	19991018	AU 1999-33766	19990331
EP 1066247	A1	20010110	EP 1999-915185	19990331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509910	T2	20020402	JP 2000-541139	19990331
US 6608067	B1	20030819	US 2000-677382	20000929
US 2004077600	A1	20040422	US 2003-614432	20030707
PRIORITY APPLN. INFO.:			US 1998-80060P	A1 19980331
			WO 1999-US7149	W 19990331
			US 2000-677382	A3 20000929

OTHER SOURCE(S): MARPAT 131:257878
TI Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus **NS3** protease
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:298250 CAPLUS
DOCUMENT NUMBER: 131:127333
TITLE: Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection
AUTHOR(S): Chien, David Y.; Arcangel, Phillip; Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark; Nguyen, Steve; George-Nascimento, Carlos; Gyenes, Alexander; Kuo, George; Valenzuela, Pablo
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94507, USA
SOURCE: Journal of Clinical Microbiology (1999), 37(5), 1393-1397
CODEN: JCMIDW; ISSN: 0095-1137
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
TI Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:231556 CAPLUS
DOCUMENT NUMBER: 130:251206
TITLE: Chemiluminescent immunoassay for detecting antibodies to **HCV**
INVENTOR(S): Chien, David Y.; Arcangel, Phillip; Tirell, Stephen; Ziegler, Wanda
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915898	A1	19990401	WO 1998-US19693	19980922
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2303123	AA	19990401	CA 1998-2303123	19980922
AU 9894979	A1	19990412	AU 1998-94979	19980922
EP 1021719	A1	20000726	EP 1998-948398	19980922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI

JP 2001517797	T2	20011009	JP 2000-513145	19980922
US 6391540	B1	20020521	US 1998-158301	19980922
US 2001039009	A1	20011108	US 2001-775962	20010202
US 6537745	B2	20030325		
US 2003170618	A1	20030911	US 2003-354476	20030128

PRIORITY APPLN. INFO.:

US 1997-59703P	P	19970922
US 1998-83921P	P	19980501
US 1998-158815	A1	19980922
WO 1998-US19693	W	19980922
US 2001-775962	A1	20010202

TI Chemiluminescent immunoassay for detecting antibodies to **HCV**

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:268513 CAPLUS

DOCUMENT NUMBER: 128:321945

TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus **NS3** protease

INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268391	AA	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 183120	A	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	B	20040107		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				
AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
NO 9901832	A	19990617	NO 1999-1832	19990416

US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 2004266731	A1	20041230	US 2003-607716	20030627

PRIORITY APPLN. INFO.:

US 1996-28290P	P	19961018
EP 1997-946273	A3	19971017
WO 1997-US18968	W	19971017
US 1999-293247	A	19990416
US 2001-875390	A3	20010606

OTHER SOURCE(S): MARPAT 128:321945

TI Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus **NS3** protease

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:337757 CAPLUS

DOCUMENT NUMBER: 125:51983

TITLE: Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease

AUTHOR(S): Bianchi, Elisabetta; Steinkueler, Christian; Taliani, Marina; Urbani, Andrea; De Francesco, Raffaele; Pessi, Antonello

CORPORATE SOURCE: Istituto Ricerche Biologia Molecolare, P. Angeletti, Rome, 00040, Italy

SOURCE: Analytical Biochemistry (1996), 237(2), 239-244
CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease

L24 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:119641 CAPLUS

DOCUMENT NUMBER: 124:199915

TITLE: Examination of IgM antibody to hepatitis C virus and analysis on hepatitis C patients' sera

AUTHOR(S): Ning, Yang; Zhao, Li; Cheng, Ming; Yang, Junying; Chen, Lailin

CORPORATE SOURCE: National Institute of Vaccine and Serum, Beijing, 100024, Peop. Rep. China

SOURCE: Zhonghua Weishengwuxue He Mianyixue Zazhi (1995), 15(4), 254-7
CODEN: ZWMZDP; ISSN: 0254-5101

PUBLISHER: Weishenbu Beijing Shengwu Zhipin Yanjiuso

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

TI Examination of IgM antibody to hepatitis C virus and analysis on hepatitis C patients' sera

L24 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:915279 CAPLUS

DOCUMENT NUMBER: 124:49963

TITLE: Evaluation of a **HCV** antibody test, "IMx·**HCV**" by enzyme immunoassay using microparticle

AUTHOR(S): Hayashi, Nobuhide; Nakamura, Isao; Ishii, Yukiko; Higashiguchi, Kanae; Mukai, Masahiko; Kumagai, Shunichi

CORPORATE SOURCE: Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan

SOURCE: Igaku to Yakugaku (1995), 34(1), 151-61
CODEN: IGYAEI; ISSN: 0389-3898

PUBLISHER: Shizen Kagakusha

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

TI Evaluation of a **HCV** antibody test, "IMx·**HCV**" by enzyme immunoassay using microparticle

L24 ANSWER 26 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:30094 BIOSIS
DOCUMENT NUMBER: PREV200600030662
TITLE: Highly sensitive FRET substrate for detection of **HCV** protease.
AUTHOR(S): Tong, X. H. [Reprint Author]; Sheng, L.; Zhong, X. F.; Tang, Y.; Lu, J.; Diwu, Z. J.; Hong, A.
CORPORATE SOURCE: AnaSpec Inc, San Jose, CA 95131 USA
SOURCE: Biopolymers, (2005) Vol. 80, No. 4, pp. 559.
Meeting Info.: 19th American Peptide Symposium. San Diego, CA, USA. June 18 -23, 2005. Amer Peptide Soc; AAPPTEC; Amer Peptide Co; Amer Hlth/GE Healthcare; Amgen Inc; BACHEM; BIOMOL Int; C S Bio Co; Cambridge Res Biochem; Chemico Int Inc; Chem Today; Eli Lilly & Co; ESCOM Sci Fdn; Genentech; Hoffman-La Roche Inc; Merck Res Lab; Midwest Bio-Tech Inc; NeoMPS Inc; New England BioLabs Inc; Novo Nordisk A/S; Peptides Int Inc; PharmaChem; PolyPeptide Lab Inc; RSP Amino Acide LLC; Senn Chem USA; Sinopep Pharmaceut Inc; SynPep Corp; Synthetech Inc; UCB Bioproducts Inc.
CODEN: BIPMAA. ISSN: 0006-3525.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 28 Dec 2005
Last Updated on STN: 28 Dec 2005
TI Highly sensitive FRET substrate for detection of **HCV** protease.

L24 ANSWER 27 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2004:1907 BIOSIS
DOCUMENT NUMBER: PREV200400003269
TITLE: **Solid phase** parallel synthesis of alpha-ketoamide inhibitors of NS3cntdot4A **HCV** protease.
AUTHOR(S): Court, John J. [Reprint Author]; Cottrell, Kevin C. [Reprint Author]; Harbeson, Scott L. [Reprint Author]; Pitlik, Janos [Reprint Author]
CORPORATE SOURCE: Department of Medicinal Chemistry, Vertex Pharmaceuticals Inc, 130 Waverly Street, Cambridge, MA, 02139, USA
john_court@vrtx.com
SOURCE: Abstracts of Papers American Chemical Society, (2003) Vol. 226, No. 1-2, pp. MEDI 97. print.
Meeting Info.: 226th ACS (American Chemical Society) National Meeting. New York, NY, USA. September 07-11, 2003. American Chemical Society.
ISSN: 0065-7727 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Dec 2003
Last Updated on STN: 17 Dec 2003
TI **Solid phase** parallel synthesis of alpha-ketoamide inhibitors of NS3cntdot4A **HCV** protease.

L24 ANSWER 28 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2000:70638 BIOSIS
DOCUMENT NUMBER: PREV200000070638
TITLE: A loop-mimetic inhibitor of the **HCV-NS3** protease derived from a minibody.
AUTHOR(S): Martin, F.; Steinkuhler, C.; Brunetti, M.; Pessi, A.; Cortese, R.; De Francesco, R.; Sollazzo, M. [Reprint author]
CORPORATE SOURCE: Istituto di Ricerche di Biologia Molecolare (IRBM) P. Angeletti, Via Pontina Km 30, 600-00040, Pomezia (Roma),

Italy
SOURCE: Protein Engineering, (Nov., 1999) Vol. 12, No. 11, pp. 1005-1011. print.
CODEN: PRENE9. ISSN: 0269-2139.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Feb 2000
Last Updated on STN: 3 Jan 2002
TI A loop-mimetic inhibitor of the **HCV-NS3** protease derived from a minibody.

L24 ANSWER 29 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:241608 BIOSIS
DOCUMENT NUMBER: PREV199900241608
TITLE: Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection.
AUTHOR(S): Chien, David Y. [Reprint author]; Arcangel, Phillip; Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark; Nguyen, Steve; George-Nascimento, Carlos; Gyenes, Alexander; Kuo, George; Valenzuela, Pablo
CORPORATE SOURCE: Life Science Center 4.302, Chiron Corporation, 4560 Horton St., Emeryville, CA, 94507, USA
SOURCE: Journal of Clinical Microbiology, (May, 1999) Vol. 37, No. 5, pp. 1393-1397. print.
CODEN: JCMIDW. ISSN: 0095-1137.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Jun 1999
Last Updated on STN: 17 Jun 1999
TI Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection.

L24 ANSWER 30 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1996:334219 BIOSIS
DOCUMENT NUMBER: PREV199699056575
TITLE: Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease.
AUTHOR(S): Bianchi, Elisabetta; Steinkuehler, Christian; Taliani, Marina; Urbani, Andrea; De Francesco, Raffaele; Pessi, Antonello [Reprint author]
CORPORATE SOURCE: Istituto di Ricerche di Biologia Molecolare P. Angeletti, Via Pontina Km 30,600, 00040 Pomezia, Rome, Italy
SOURCE: Analytical Biochemistry, (1996) Vol. 237, No. 2, pp. 239-244.
CODEN: ANBCA2. ISSN: 0003-2697.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 26 Jul 1996
Last Updated on STN: 27 Jul 1996
TI Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease.

L24 ANSWER 31 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1996:221512 BIOSIS
DOCUMENT NUMBER: PREV199698777641
TITLE: IgM antibody response to hepatitis C virus in end-stage renal disease.
AUTHOR(S): Fabrizi, F. [Reprint author]; Lunghi, G.; Guarnori, I.; Raffaele, L.; Erba, G.; Pagano, A.; Locatelli, F.
CORPORATE SOURCE: Nephrol. Dep., Hosp. of Lecco, via Ghislanzoni 22, 22053 Lecco, Italy
SOURCE: Nephrology Dialysis Transplantation, (1996) Vol. 11, No. 2, pp. 314-318.
ISSN: 0931-0509.
DOCUMENT TYPE: Article

LANGUAGE: English
ENTRY DATE: Entered STN: 8 May 1996
Last Updated on STN: 8 May 1996
TI IgM antibody response to hepatitis C virus in end-stage renal disease.

L24 ANSWER 32 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1995:486794 BIOSIS
DOCUMENT NUMBER: PREV199598501094
TITLE: Examination of IgM antibody to hepatitis C and analysis on hepatitis C patients' sera.
AUTHOR(S): Ning, Yang; Zhao; Li; Cheng; Ming
CORPORATE SOURCE: National Vaccine Serum Inst., Beijing 100024, China
SOURCE: Zhonghua Weishengquxue He Mianyixue Zazhi, (1995) Vol. 15, No. 4, pp. 254-257.
CODEN: ZWMZDP. ISSN: 0254-5101.
DOCUMENT TYPE: Article
LANGUAGE: Chinese
ENTRY DATE: Entered STN: 9 Nov 1995
Last Updated on STN: 9 Nov 1995
TI Examination of IgM antibody to hepatitis C and analysis on hepatitis C patients' sera.

L24 ANSWER 33 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:367187 BIOSIS
DOCUMENT NUMBER: PREV199396052862
TITLE: Evaluation of three recombinant antigens for detection of antibodies to hepatitis C virus.
AUTHOR(S): Cheng, Da-Rong
CORPORATE SOURCE: Natl. Vaccine Serum Inst., Beijing, China
SOURCE: Chinese Journal of Microbiology and Immunology (Beijing), (1993) Vol. 13, No. 2, pp. 97-100.
DOCUMENT TYPE: Article
LANGUAGE: Chinese
ENTRY DATE: Entered STN: 6 Aug 1993
Last Updated on STN: 6 Aug 1993
TI Evaluation of three recombinant antigens for detection of antibodies to hepatitis C virus.

L24 ANSWER 34 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:187917 BIOSIS
DOCUMENT NUMBER: PREV199395098367
TITLE: Synthesis and antigenic activity of the peptides from the core and **NS3** proteins of the hepatitis C virus.
AUTHOR(S): Semiletov, Yu. A.; Firsova, T. V.; Shibnev, V. A.; Vyazov, S. O.
CORPORATE SOURCE: D.I. Ivanovskii Inst. Virol., Acad. Med. Sci. Russ., Moscow, Russia
SOURCE: Bioorganicheskaya Khimiya, (1993) Vol. 19, No. 1, pp. 126-129.
CODEN: BIKHD7. ISSN: 0132-3423.
DOCUMENT TYPE: Article
LANGUAGE: Russian
ENTRY DATE: Entered STN: 9 Apr 1993
Last Updated on STN: 9 Apr 1993
TI Synthesis and antigenic activity of the peptides from the core and **NS3** proteins of the hepatitis C virus.